Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Small Cell Lung Carcinoma 3Radiation Pneumonitis 2Mesothelioma, Malignant 2Lung Neoplasms 2Recurrence 1Mesothelioma 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 71Paclitaxel 49Radiotherapy 44Pemetrexed 42Cisplatin 41Bevacizumab 39Gemcitabine 27Docetaxel 27Erlotinib Hydrochloride 23Gefitinib 18pembrolizumab 14Taxes 13Vinorelbine 10Cetuximab 10Radiation 8Nivolumab 8Magnetic Resonance Spectroscopy 8capmatinib 7Radiosurgery 7Platinum 7Etoposide 7Surgical Procedures, Operative 6Radiotherapy, Conformal 6Mastectomy, Segmental 6ceritinib 5aflutinib 5Specimen Handling 5Neoadjuvant Therapy 5Cyclophosphamide 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × nintedanib × Thoracic × Clear all
NCT03361319 2020-11-24

N3

Royal Marsden NHS Foundation Trust

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡